tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Cue Biopharma (CUE), Catalyst Pharma (CPRX) and Anixa Biosciences (ANIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cue Biopharma (CUEResearch Report), Catalyst Pharma (CPRXResearch Report) and Anixa Biosciences (ANIXResearch Report) with bullish sentiments.

Cue Biopharma (CUE)

In a report released today, Michael King from H.C. Wainwright reiterated a Buy rating on Cue Biopharma, with a price target of $20.00. The company’s shares closed last Thursday at $5.52, close to its 52-week low of $4.29.

According to TipRanks.com, King is a 4-star analyst with an average return of 8.9% and a 44.1% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics.

Cue Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $27.20.

See the top stocks recommended by analysts >>

Catalyst Pharma (CPRX)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Catalyst Pharma, with a price target of $12.00. The company’s shares closed last Thursday at $7.39.

According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -5.4% and a 36.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.

Currently, the analyst consensus on Catalyst Pharma is a Strong Buy with an average price target of $10.38, which is a 39.9% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $8.75 price target.

Anixa Biosciences (ANIX)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences today and set a price target of $11.00. The company’s shares closed last Thursday at $2.74, close to its 52-week low of $2.30.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 6.3% and a 35.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Anixa Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CUE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More